Table 6.

Haplotype analysis of association between MIR17HG polymorphisms and colorectal cancer risk

SNP‐ID	Haplotype	Overall				Rectal cancer				Male
		Case	Control	OR (95% CI)	p	Case	Control	OR (95% CI)	p	Case	Control	OR (95% CI)	p
rs72640334|	CTAGA	0.558	0.496	1.26 (1.06–1.49)	0.007	0.564	0.496	1.29 (1.04–1.59)	0.018	0.544	0.469	1.32 (1.06–1.65)	0.015
rs7336610|	CCAAC	0.834	0.812	1.17 (0.93–1.47)	0.183	0.846	0.812	1.27 (0.95–1.70)	0.113	0.832	0.799	1.24 (0.92–1.67)	0.160
rs7318578|	ACCGC	0.917	0.904	1.17 (0.86–1.58)	0.323	0.918	0.904	1.18 (0.81–1.73)	0.394	0.905	0.897	1.09 (0.74–1.61)	0.657
rs17735387|	CCCGC	0.824	0.799	1.18 (0.94–1.49)	0.148	0.823	0.799	1.19 (0.89–1.58)	0.250	0.827	0.792	1.28 (0.94–1.75)	0.118
rs1428	CCAGC	0.983	0.981	1.12 (0.58–2.18)	0.739	0.977	0.981	0.82 (0.38–1.74)	0.598	0.981	0.981	0.99 (0.42–2.32)	0.980

SNP: Single nucleotide polymorphism; OR: Odds ratio; 95% CI: 95% Confidence interval

OR and 95% CI were calculated using logistic regression adjusted with age and gender.

p < 0.05 was considered statistically significant.